logo

ADCT

ADC Therapeutics·NYSE
--
--(--)
--
--(--)
5.99 / 10
Netural

Financial evaluation rates ADC Therapeutics at 6.0/10, highlighting a solid interest coverage ratio of 15.48% and positive Profit-MV, yet hampered by elevated Days sales outstanding at 100.11 days, which historically correlates with negative returns. Revenue growth is modest at 8.11% YoY, and several valuation metrics (Revenue-MV, Cash-MV, PB-ROE) fall in lower quartiles, signaling mixed fundamental quality. Investors should note the accounts-receivable inefficiency as a key downside risk.

Fundamental(5.99)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-1.35
Score2/3
Weight14.47%
1M Return7.73%
Total operating revenue (YoY growth rate %)
Value8.11
Score2/3
Weight1.58%
1M Return1.11%
Days sales outstanding
Value100.11
Score0/3
Weight-6.53%
1M Return-5.18%
Profit-MV
Value0.46
Score2/3
Weight14.75%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight14.76%
1M Return8.45%
PB-ROE
Value0.32
Score3/3
Weight20.00%
1M Return12.83%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.48%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value8.11
Score2/3
Weight0.61%
1M Return0.43%
Asset-MV
Value-0.50
Score3/3
Weight27.34%
1M Return13.15%
Cash-MV
Value-0.07
Score2/3
Weight14.50%
1M Return8.41%
Is ADCT fundamentally strong?
  • ADCT scores 5.99/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -221.97% net margin, -2.65 P/E ratio, -1.89 P/B ratio, and 41.00% earnings growth, these metrics solidify its Netural investment rating.